The pros and cons need to be weighed in the use of TPO-RAs on patients with transient CIT because they usually do not require treatment for CIT unless they develop bleeding in association with the CIT or they have profound nadir thrombocytopenia (typically a platelet count <20–30 × 109/L) (Al-Samkari, 2024). The gene discussed is TPO; the disease is Thrombocytopenia.